10-K/A: Celularity Inc. Amends Annual Report, Details Governance & Debt

Celularity Inc. files an amendment to its 2025 Form 10-K, primarily to include Part III information, detailing executive officers, corporate governance, and extensive related-party transactions and financing agreements.

Summary

• Celularity Inc. has filed an Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2025, to incorporate Part III information, including details on directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and accounting fees.
• The filing details the current executive team and board of directors, including their backgrounds and responsibilities.
• Significant focus is placed on corporate governance, including board leadership structure, risk oversight, and committee compositions (Audit, Compensation, Nominating and Corporate Governance).
• Extensive information is provided on executive and director compensation, including salary, stock awards, and option awards for the fiscal years 2025 and 2024.
• The report details numerous related-party transactions, primarily involving bridge loans and securities purchase agreements with entities and trusts associated with significant shareholders and directors, such as Dragasac Limited, C.V. Starr & Co., Inc., Resorts World Inc Pte Ltd, and the Philip & Daniele Barach Family Trust.
• Details on outstanding equity awards as of December 31, 2025, are provided for named executive officers.
• The company's independent registered public accounting firm for 2024 and 2025 was EisnerAmper LLP.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the extensive discussion of debt, financing arrangements, and potential dilutive effects, overshadowing the corporate governance and executive compensation details.

Positives

• The filing provides a comprehensive update on the company's leadership and governance structure, ensuring transparency for stakeholders.
• Detailed executive compensation information is disclosed, aligning with regulatory requirements and providing insight into management incentives.
• The company has adopted a compensation recovery policy to comply with Rule 10D-1 of the Exchange Act, enhancing accountability.
• The board of directors has established clear policies for risk oversight, with the audit committee playing a primary role.
• The company has a written code of business conduct and ethics applicable to all directors, officers, and employees.

Negatives

• The filing extensively details numerous related-party financing agreements, including bridge loans and convertible notes, with significant associated interest rates and warrants, indicating a reliance on related parties for funding.
• Several financing agreements with related parties, such as C.V. Starr & Co., Inc. and Resorts World Inc Pte Ltd, have been amended and include forbearance agreements due to defaults or potential defaults related to liquidity covenants.
• The company has issued a substantial number of warrants in connection with these financing arrangements, which could lead to significant future dilution for existing shareholders.
• The Philip & Daniele Barach Family Trust has entered into multiple significant financing agreements, including a $7 million Senior Note and a $3 million Convertible Note, and later an amended and restated convertible note and warrant as part of a larger $25 million financing.
• The company's financial condition appears strained, evidenced by the reclassification of loans as current liabilities due to covenant breaches and the ongoing need for related-party financing.

Risks

• The issuance of numerous warrants in connection with related-party financing agreements poses a significant risk of dilution to existing Class A common stock shareholders.
• The company's reliance on related-party financing, coupled with past covenant breaches on liquidity, suggests potential ongoing financial instability and a risk of further defaults.
• The ability of the board of directors to issue preferred stock without stockholder approval could adversely affect the voting power and rights of Class A common stock holders and potentially have anti-takeover effects.
• The exclusive forum selection provision in the certificate of incorporation may discourage lawsuits against directors and officers, potentially reducing accountability.
• The company is subject to Section 203 of the DGCL, which regulates corporate takeovers and may make it more difficult for a third party to acquire the company.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. It primarily focuses on corporate structure, governance, and past transactions.

Management Comments

• StockSavvy.ai notes that the company's board believes combining the CEO and Board Chair positions ensures a common purpose and clear chain of command for executing strategic initiatives.
• The board believes that having a Board Chair with extensive company history and knowledge is advantageous compared to a less informed independent Chair.
• Management believes the company's compensation programs are designed to encourage executives and employees to focus on both short-term and long-term strategic goals, promoting a pay-for-performance philosophy.
• The company believes its limitations of liability and indemnification provisions are necessary to attract and retain qualified directors and officers.

Industry Context

StockSavvy.ai observes that Celularity Inc. operates in the biotechnology sector, which is characterized by high R&D costs, complex regulatory pathways, and significant capital requirements. The extensive related-party financing and warrant issuances detailed in this filing are not uncommon in early-stage or financially challenged biotech companies seeking to bridge funding gaps, though they often come with substantial dilution risks for existing shareholders.

Comparison to Industry Standards

• The compensation structure for executives, including base salary, stock awards, and option awards, appears to be within the typical range for biotechnology companies of similar size and stage, though specific peer comparisons are not provided.
• The company's reliance on bridge loans and convertible notes, particularly from related parties, is a common, albeit often dilutive, financing strategy in the biotech sector when traditional equity markets are less accessible or favorable.
• The governance structure, including the establishment of audit, compensation, and nominating/corporate governance committees, aligns with standard corporate governance practices for publicly traded companies in the U.S.

Management Changes

Corporate Governance

Legal Proceedings

• The filing states that, except as otherwise disclosed in Item 3 (Legal Proceedings) of the original Form 10-K, there is no pending litigation or proceeding involving any of the company's directors or executive officers as to which indemnification is required or permitted, and the company is not aware of any threatened litigation or proceeding that may result in a claim for indemnification.

Related Party Transactions

• Bridge loan agreements and securities purchase agreements with C.V. Starr & Co., Inc., a beneficial owner of more than 5% of common stock.
• Senior secured bridge loan agreements and subsequent amendments/forbearance agreements with Resorts World Inc Pte Ltd (RWI), affiliated with Lim Kok Thay.
• Financing agreements with the Philip & Daniele Barach Family Trust, including senior secured and convertible promissory notes, and warrants.
• The Philip A. Barach Family Trust is a significant shareholder and Mr. Barach is a director, involved in multiple financing and governance agreements.
• Employment of Alexandra Hariri, daughter of CEO Robert J. Hariri, as Senior Vice President, Corporate Development.
• The company has a written related-party transactions policy reviewed by the audit committee.

Stakeholder Impact

• Shareholders face potential dilution from the extensive issuance of warrants tied to financing agreements.
• Creditors and lenders, particularly related parties, have secured interests in company assets, impacting the priority of other potential creditors.
• Employees' compensation and benefits are detailed, with equity awards intended to align interests.
• Directors and officers are subject to indemnification agreements and limitations on liability, potentially impacting their willingness to serve but also potentially reducing litigation risk for the company.

Next Steps

• The company will continue to operate under its current board and executive leadership structure.
• The company will manage its ongoing financing obligations and related-party agreements.
• The company will continue to comply with SEC reporting requirements.

Key Dates

Recommendation

The filing reveals significant financial challenges, evidenced by heavy reliance on related-party debt with high interest rates and extensive warrant issuance, leading to potential dilution. While corporate governance details are provided, the financial strain and dilutive nature of past financing warrant a cautious 'hold' stance until a clearer path to sustainable operations and profitability emerges.

Keywords

Celularity Inc., Form 10-K/A, Annual Report, Corporate Governance, Executive Compensation, Related Party Transactions, Financing Agreements, Class A Common Stock